We are now entering the final stage of our pivotal Phase 3 trial DIAGNODE-3—a landmark study in precision medicine for type 1 diabetes evaluating retogatein (rhGAD65), our investigational antigen-specific immunotherapy. Patient screening has been completed, a monumental achievement that reflects the dedication and coordination of our internal team, investigators, and partners across Europe and the U.S., and I extend my sincere gratitude to...